Sievers, E. L., Larson, R. A., Estey, E., Lowenberg, B., Erba, H. P., Gramatzki, M., … Appelbaum, F. R. (2000). Prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin (Mylotarg (TM), CMA-676) followed by hematopoietic stem cell transplantation. In BLOOD (Vol. 96, pp. 320A-320A). AMER SOC HEMATOLOGY.

Sievers, E. L., R. A. Larson, E. Estey, B. Lowenberg, H. P. Erba, M. Gramatzki, A. List, et al. “Prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin (Mylotarg (TM), CMA-676) followed by hematopoietic stem cell transplantation.” In BLOOD, 96:320A-320A. AMER SOC HEMATOLOGY, 2000.

Sievers EL, Larson RA, Estey E, Lowenberg B, Erba HP, Gramatzki M, et al. Prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin (Mylotarg (TM), CMA-676) followed by hematopoietic stem cell transplantation. In: BLOOD. AMER SOC HEMATOLOGY; 2000. p. 320A-320A.

Sievers, E. L., et al. “Prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin (Mylotarg (TM), CMA-676) followed by hematopoietic stem cell transplantation.” BLOOD, vol. 96, no. 11, AMER SOC HEMATOLOGY, 2000, pp. 320A-320A.

Sievers EL, Larson RA, Estey E, Lowenberg B, Erba HP, Gramatzki M, List A, Sierra J, Stadtmauer EA, Tarantolo S, Berger MS, Leopold LH, Eten C, Munteanu M, Stone A, Bernstein ID, Appelbaum FR. Prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin (Mylotarg (TM), CMA-676) followed by hematopoietic stem cell transplantation. BLOOD. AMER SOC HEMATOLOGY; 2000. p. 320A-320A.